Varian, a Siemens Healthineers company, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of low-dose radiation therapy with its Varian TrueBeam radiotherapy systems in adults with medically refractory osteoarthritis.
The clearance covers the TrueBeam, TrueBeam STx, VitalBeam, and Edge systems and marks an expansion of the TrueBeam platform beyond oncology into chronic musculoskeletal conditions. The indication is intended for patients who continue to experience pain and reduced mobility despite other treatments, Siemens Healthineers said.
The clearance builds on an earlier non-oncological approval for the TrueBeam platform covering radiosurgery treatment for medically refractory essential tremor in adults.
